Redhill Biopharma Ltd-sp Adr (RDHL)

$0.4

+0.02

(+4.42%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.37
    $0.43
    $0.40
    downward going graph

    6.5%

    Downside

    Day's Volatility :12.0%

    Upside

    5.88%

    downward going graph
  • $0.26
    $3.28
    $0.40
    downward going graph

    35.75%

    Downside

    52 Weeks Volatility :92.16%

    Upside

    87.8%

    downward going graph

Returns

PeriodRedhill Biopharma Ltd-sp AdrSector (Health Care)Index (Russel 2000)
3 Months
-11.21%
6.5%
0.0%
6 Months
-44.13%
7.1%
0.0%
1 Year
-71.64%
9.8%
0.0%
3 Years
-99.86%
14.2%
-20.2%

Highlights

Market Capitalization
11.2M
Book Value
$0.11
Earnings Per Share (EPS)
4.0
PE Ratio
0.09
PEG Ratio
0.0
Wall Street Target Price
760.0
Profit Margin
366.25%
Operating Margin TTM
-1060.79%
Return On Assets TTM
-15.71%
Return On Equity TTM
-884.29%
Revenue TTM
6.5M
Revenue Per Share TTM
1.01
Quarterly Revenue Growth YOY
-95.6%
Gross Profit TTM
45.3M
EBITDA
-22.2M
Diluted Eps TTM
4.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Redhill Biopharma Ltd-sp Adr(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 189900.0%

Current $0.40
Target $760.00

Company Financials

FY18Y/Y Change
Revenue
8.4M
↑ 108.63%
Net Income
-38.8M
↓ 14.76%
Net Profit Margin
-464.35%
↑ 672.26%
FY19Y/Y Change
Revenue
6.3M
↓ 24.75%
Net Income
-43.6M
↑ 12.4%
Net Profit Margin
-693.59%
↓ 229.24%
FY20Y/Y Change
Revenue
64.4M
↑ 923.03%
Net Income
-89.0M
↑ 104.01%
Net Profit Margin
-138.31%
↑ 555.28%
FY21Y/Y Change
Revenue
85.8M
↑ 33.25%
Net Income
-114.3M
↑ 28.41%
Net Profit Margin
-133.3%
↑ 5.01%
FY22Y/Y Change
Revenue
61.8M
↓ 27.94%
Net Income
-59.2M
↓ 48.17%
Net Profit Margin
-95.87%
↑ 37.43%
FY23Y/Y Change
Revenue
6.5M
↓ 89.46%
Net Income
23.9M
↓ 140.37%
Net Profit Margin
367.19%
↑ 463.06%
Q1 FY22Q/Q Change
Revenue
18.2M
↓ 17.38%
Net Income
-21.0M
↓ 13.69%
Net Profit Margin
-115.35%
↓ 4.92%
Q2 FY22Q/Q Change
Revenue
18.3M
↑ 0.6%
Net Income
-14.3M
↓ 32.2%
Net Profit Margin
-77.74%
↑ 37.61%
Q3 FY22Q/Q Change
Revenue
18.3M
↑ 0.0%
Net Income
-14.3M
↑ 0.0%
Net Profit Margin
-77.74%
↑ 0.0%
Q4 FY22Q/Q Change
Revenue
12.8M
↓ 30.24%
Net Income
2.5M
↓ 117.46%
Net Profit Margin
19.46%
↑ 97.2%
Q1 FY23Q/Q Change
Revenue
12.8M
↑ 0.0%
Net Income
2.5M
↑ 0.0%
Net Profit Margin
19.46%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
1.8M
↓ 85.97%
Net Income
761.0K
↓ 69.44%
Net Profit Margin
42.37%
↑ 22.91%
FY18Y/Y Change
Total Assets
62.4M
↑ 8.84%
Total Liabilities
11.2M
↓ 8.58%
FY19Y/Y Change
Total Assets
74.1M
↑ 18.73%
Total Liabilities
14.1M
↑ 25.59%
FY20Y/Y Change
Total Assets
180.2M
↑ 143.24%
Total Liabilities
166.4M
↑ 1080.23%
FY21Y/Y Change
Total Assets
181.2M
↑ 0.53%
Total Liabilities
172.3M
↑ 3.57%
FY22Y/Y Change
Total Assets
158.9M
↓ 12.32%
Total Liabilities
207.3M
↑ 20.29%
FY23Y/Y Change
Total Assets
23.0M
↓ 85.49%
Total Liabilities
21.0M
↓ 89.88%
Q1 FY22Q/Q Change
Total Assets
167.0M
↓ 7.8%
Total Liabilities
172.3M
↓ 0.01%
Q2 FY22Q/Q Change
Total Assets
168.0M
↑ 0.55%
Total Liabilities
179.9M
↑ 4.42%
Q3 FY22Q/Q Change
Total Assets
168.0M
↑ 0.0%
Total Liabilities
179.9M
↑ 0.0%
Q4 FY22Q/Q Change
Total Assets
158.9M
↓ 5.42%
Total Liabilities
207.3M
↑ 15.21%
Q1 FY23Q/Q Change
Total Assets
158.9M
↑ 0.0%
Total Liabilities
207.3M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
35.0M
↓ 77.95%
Total Liabilities
31.6M
↓ 84.77%
FY18Y/Y Change
Operating Cash Flow
-34.5M
↓ 23.02%
Investing Cash Flow
5.4M
↓ 128.8%
Financing Cash Flow
41.8M
↑ 62.8%
FY19Y/Y Change
Operating Cash Flow
-40.7M
↑ 18.24%
Investing Cash Flow
5.2M
↓ 3.51%
Financing Cash Flow
35.5M
↓ 14.97%
FY20Y/Y Change
Operating Cash Flow
-48.6M
↑ 19.22%
Investing Cash Flow
-35.6M
↓ 790.34%
Financing Cash Flow
84.4M
↑ 137.6%
FY21Y/Y Change
Operating Cash Flow
-65.0M
↑ 33.9%
Investing Cash Flow
-8.1M
↓ 77.17%
Financing Cash Flow
73.5M
↓ 12.93%
Q1 FY22Q/Q Change
Operating Cash Flow
-4.2M
↓ 72.04%
Investing Cash Flow
8.5M
↑ 142.69%
Financing Cash Flow
-4.9M
↓ 128.14%
Q2 FY22Q/Q Change
Operating Cash Flow
-16.6M
↑ 299.06%
Investing Cash Flow
-163.0K
↓ 101.92%
Financing Cash Flow
14.9M
↓ 401.72%
Q3 FY22Q/Q Change
Operating Cash Flow
-6.0M
↓ 63.65%
Investing Cash Flow
-22.0K
↓ 86.5%
Financing Cash Flow
-5.7M
↓ 138.35%

Technicals Summary

Sell

Neutral

Buy

Redhill Biopharma Ltd-sp Adr is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Redhill Biopharma Ltd-sp Adr
Redhill Biopharma Ltd-sp Adr
2.12%
-44.13%
-71.64%
-99.86%
-99.86%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.56%
2.78%
45.55%
52.55%
67.01%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.53%
11.87%
3.28%
23.35%
23.35%
Zoetis Inc.
Zoetis Inc.
5.77%
-5.62%
-5.85%
-9.99%
57.03%
Viatris Inc.
Viatris Inc.
12.75%
-1.42%
12.21%
-15.03%
-28.03%
Catalent, Inc.
Catalent, Inc.
4.08%
11.91%
19.53%
-48.27%
2.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Redhill Biopharma Ltd-sp Adr
Redhill Biopharma Ltd-sp Adr
0.09
0.09
0.0
0.0
-8.84
-0.16
NA
0.11
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.75
39.75
0.44
3.99
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.9
29.9
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.62
34.62
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Redhill Biopharma Ltd-sp Adr
Redhill Biopharma Ltd-sp Adr
Buy
$11.2M
-99.86%
0.09
366.25%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
67.01%
39.75
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$41.0B
23.35%
29.9
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.0B
57.03%
34.62
27.38%
Viatris Inc.
Viatris Inc.
Hold
$14.2B
-28.03%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.6B
2.08%
211.02
-28.44%

Insights on Redhill Biopharma Ltd-sp Adr

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 18.34M → 1.79M (in $), with an average decrease of 38.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 2.49M → 761.0K (in $), with an average decrease of 69.4% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 117.1%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 152.5%

Institutional Holdings

  • Sabby Management LLC

    7.28%

  • Gagnon Securities LLC

    0.37%

  • JANE STREET GROUP, LLC

    0.27%

  • UBS Group AG

    0.16%

  • Rhumbline Advisers

    0.09%

  • Virtu Financial LLC

    0.07%

Company Information

redhill biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. redhill has an experienced management team, board of directors and advisory board based in israel, the us, canada and europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise

Organization
Redhill Biopharma Ltd-sp Adr
Employees
53
CEO
Mr. Dror Ben-Asher
Industry
Health Technology

Discover More

FAQs